The Spanish company Peaches Biotech deciphers the language that immune cells use to communicate with different tissues
Peaches Biotech publishes in Biomolecules its work on how the immune system communicates with tissues that have been damaged or attacked by viruses or bacteria
The Peaches Biotech drug belongs to a new generation of biological complex pharmaceuticals that come from co-culture methods inside which the communication between macrophages and damaged tissue cells is reproduced
Peaches Biotech Group, a Spanish company specialized in innovative treatments with regenerative medicine and advanced therapies, announces the publication of an article in the journal Biomolecules of the MDPI scientific editorial group entitled "Production of a new anti-inflammatory biological drugs”. The publication collects its work based on the communication between macrophages and mesenchymal cells with which it will develop the first biological immunomodulatory and anti-inflammatory drug that will treat the cytokine storm.
The article explains how the Peaches Biotech company has deciphered the language with which immune cells communicate with different tissues. This scientific contribution is of great relevance, since it opens up a new path to obtain pharmaceutical drugs of biological origin that will lead to more effective therapies in highly prevalent pathologies which currently lack effective treatments.
As demonstrated in Biomolecules, intercellular communication between macrophages and cells involved in tissue regeneration, such as adult mesenchymal stromal cells and primary tissue cells, is essential for tissue regeneration.
To furthermore understand this communication and obtain the message between immune cells – macrophages – and tissue cells that have been damaged or attacked by pathogens, Peaches Biotech recreates the same conditions that occur inside our own body in a cell co-culture enviroment.
The Peaches Biotech co-culture concept
The message between M2 macrophages and tissue cells is made up of a complex set of cytokines, chemokines and growth factors that form the secretome of the co-culture and that will make way for this new drug. The intercellular communication is what drives an immunomodulatory and anti-inflammatory response.
The first of these new sets of drugs that Peaches Biotech is working on is PRS® CK-Storm and derives from the co-culture of M2 macrophages with adult mesenchymal cells (MSCs).
The PRS® CK-Storm will shortly begin its trials in several hospitals inside the Madrid region (Spain) intended towards the treatment of cytokine storm, initially with COVID-19 patients.
PRS® CK-Storm not only fights the proinflammatory response of cytokines, but also improves the regenerative activity of damaged lung tissue after the disease in COVID-19 patients.
This same method would be applied to other pathologies where cytokine storms occur, such as pancreatitis or those caused by other septic infections.
About the cytokine storm
Inflammation is the immune system´s response of damage to its cells and tissues occurred by bacterial pathogens or any other biological, chemical, physical, or mechanical aggressor. Such inflammatory response must be self-limited in time and intensity since, should there not be a perfect coordination given between the given and adaptive immune systems, a severe inflammatory syndrome will take place, eventually developing in a cytokine storm that can lead to multi-organ failure. Peaches Biotech has managed to neutralize the proinflammatory reaction produced by this overreaction of the immune system both in in animal and in vitro models.
For further information:
Alfonso Ortín
PR Manager
About Peaches Biotech Group
We are focused on the creation of drugs based on advanced therapies, especially with cytokines, stem cells or T-lymphocytes, which will allow patients to take advantage of new therapeutic options that are cost-effective and break with current models.